{"schema_version":"secwatch.filing_event.v1","accession":"0001785530-23-000034","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.435821+00:00","generated_at":"2026-06-08T03:54:46.438081+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Werewolf Therapeutics Q3 net loss $8.3M; WTX-124 shows early antitumor activity","bullets":["Cash $130.1M as of Sep 30; sufficient to fund operations through Q4 2024.","Collaboration revenue $5.9M (vs $5.0M prior year); net loss $8.3M (vs $11.9M).","WTX-124 Phase 1 data: well-tolerated, two unconfirmed partial responses at 12 mg, no Grade 3+ related AEs.","WTX-330 dose escalation ongoing; WTX-124 expansion expected to open in H1 2024.","New pipeline candidate WTX-518 (IL-18 INDUKINE) added; preclinical data in H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001785530-23-000034","json":"https://secwatch.observer/filing/0001785530-23-000034.json","markdown":"https://secwatch.observer/filing/0001785530-23-000034.md","text":"https://secwatch.observer/filing/0001785530-23-000034.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000034/0001785530-23-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000034/howl-20231114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:54:46.438081+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f10b5cc30a059de4c94bfbe12c9f5d43f4001f70","claim":"Werewolf Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $5.9 million.","evidence_excerpt":"Collaboration revenue was $5.9 million for the third quarter of 2023, compared to $5.0 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1785530/000178553023000034/0001785530-23-000034-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$5.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}